Eledon Pharmaceuticals, Inc. ELDN
We take great care to ensure that the data presented and summarized in this overview for Eledon Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ELDN
View all-
Bvf Inc San Francisco, CA6.29MShares$28.5 Million0.96% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.57MShares$16.2 Million0.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.89MShares$13.1 Million0.0% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L32.55MShares$11.6 Million2.15% of portfolio
-
First Light Asset Management, LLC Edina, MN2.33MShares$10.5 Million0.93% of portfolio
-
Blue Owl Capital Holdings LP New York, NY1.96MShares$8.88 Million3.43% of portfolio
-
Woodline Partners LP San Francisco, CA1.67MShares$7.57 Million0.05% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY1.52MShares$6.87 Million0.04% of portfolio
-
Ensign Peak Advisors, Inc Salt Lake City, UT1.26MShares$5.73 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.18MShares$5.33 Million0.29% of portfolio
Latest Institutional Activity in ELDN
Top Purchases
Top Sells
About ELDN
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Insider Transactions at ELDN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 09
2024
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,927,937
+24.25%
|
-
|
|
May 05
2023
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,978,932
+33.36%
|
-
|
|
Nov 23
2022
|
Steven Perrin President |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$2,000
$2.6 P/Share
|
|
Dec 20
2021
|
David Alexandre C Gros Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+18.18%
|
$8,000
$4.48 P/Share
|
|
Aug 17
2021
|
David Alexandre C Gros Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
4,000
+36.36%
|
$24,000
$6.21 P/Share
|
|
Jun 11
2021
|
Paul Sean Little Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$80,000
$8.87 P/Share
|
|
Jun 09
2021
|
David Alexandre C Gros Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+50.0%
|
$24,000
$8.01 P/Share
|
|
Dec 22
2020
|
Bvf Partners L P > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,289,628
+28.66%
|
-
|
|
Dec 02
2020
|
Orbi Med Israel Gp Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
103,200
-58.35%
|
$2,167,200
$21.6 P/Share
|
|
Oct 30
2020
|
Logos Global Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
92,040
+6.21%
|
$2,301,000
$25.52 P/Share
|
|
Oct 30
2020
|
Logos Global Management LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
12,969
-3.24%
|
$337,194
$26.83 P/Share
|
|
Jul 15
2015
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,566
-0.08%
|
$49,924
$14.26 P/Share
|
|
Jul 14
2015
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
27,861
-0.62%
|
$390,054
$14.41 P/Share
|
|
Jul 13
2015
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
20,611
-0.45%
|
$288,554
$14.2 P/Share
|
|
Jun 16
2015
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,120
-0.02%
|
$15,680
$14.27 P/Share
|
|
Jun 12
2015
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,919
-0.13%
|
$82,866
$14.2 P/Share
|
|
Jun 11
2015
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
27,875
-0.61%
|
$390,250
$14.2 P/Share
|
|
Mar 19
2015
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
46,141
-0.99%
|
$645,974
$14.5 P/Share
|
|
Mar 18
2015
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,000
-0.06%
|
$42,000
$14.5 P/Share
|
|
Sep 22
2014
|
Novartis Bioventures LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
325,000
+6.54%
|
$4,875,000
$15.0 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 1.93M shares |
|---|